While talks of a rumored swap between Merck's consumer-goods business and Novartis' animal health and vaccines units have cooled, sources now tell The Wall Street Journal they expect industry heavyweights to put in bids that could surpass $10 billion, and Merck has already received preliminary offers for the business.
Johnson & Johnson and Pharmacyclics' new drug Imbruvica won the expanded approval it needed to go beyond a rare disease treatment and reach the blockbuster status it was conceived for. The FDA Wednesday gave Imbruvica accelerated approval for treating chronic lymphocytic leukemia in patients who have received at least one previous therapy.
Copay coupons and discount cards could soon be seeing the end of their day as pharmacy benefits managers put their foot down.
You're trying to jump-start sales of a drug that never has hummed on all cylinders, but now, you're seeing signs of life. Then the feds show up, digging into the study data that justified that drug's FDA approval. That's the conundrum facing AstraZeneca and its Brilinta blood thinner, now under investigation by the Justice Department.
What will Sanofi do with its cash? That's the question now that L'Oreal seems happy to remain the French drugmaker's largest shareholder. Absent the need to hoard cash to buy back L'Oreal shares, at least for now, Sanofi can use that money for something else.
Want the latest on Novartis' should-we-or-shouldn't-we asset review? Leerink Partners analysts met with CEO Joe Jimenez recently, so they can deliver that and more, including some hints at cost-cutting targets.
Nothing makes analysts happier these days than a prospective spinoff. And with a new chairman stepping in to help conduct the ongoing strategic review of the struggling Reckitt Benckiser pharma unit, some say one could be on the way for the British group.
Gilead Sciences is starting to make some noise about Sovaldi's prospects: On Tuesday, CEO John Milligan told Reuters he still won't make a definitive sales projection about the drug, but he doesn't disagree with analysts' estimates.
Bayer's painkiller Aleve carries the same heart-risk warning as other nonsteroidal anti-inflammatories, or NSAIDs, like Motrin and Advil. And as far as an FDA review panel of experts is concerned, it should continue to.
AstraZeneca's diabetes drug Onglyza is under the FDA's microscope. The agency said it would review possible heart risks associated with the medication, which is one of the cornerstone products in the U.K.-based drugmaker's diabetes business.
The number of new drug shortages in the U.S. has fallen dramatically during the last few years. Still, the total number of shortages keeps growing, leaving doctors to figure out how to change treatment plans when meds are unavailable.
The U.K.'s National Health Service hired a lobbying group, Specialised Healthcare Alliance (SHCA), to write a report on strategies for care, which could influence health policy, The Guardian reports.
Are the BRIC countries passé in Big Pharma? Not exactly. But multinational pharma's newest trend lies in the Persian Gulf, the Wall Street Journal reports.
When Merck & Co. suddenly took over Merck KGaA's Facebook page, that was one thing. But when demonstrators showed up at the German Merck's London office--to protest a move by the U.S.-based Merck--that was something else entirely.
Mallinckrodt has taken a major step toward hitting its goal of boosting revenues as much as 11% a year by announcing it would acquire Cadence Pharmaceuticals for $1.3 billion, or $14 a share, a 26% premium over Cadence's closing price yesterday.
Federal prosecutors are eyeing Teva Pharmaceutical Industries for potential marketing violations.
Late last year, FDA Commissioner Margaret Hamburg's first official trip to India was postponed for undisclosed reasons. It was rescheduled and now happens to coincide with actions designed to put ultimate pressure on India over its low regard for patents on drugs that it thinks are too expensive.
If Big Pharma should consider hiving off extraneous business units, then why not Big Generics? Goldman Sachs analyst Jami Rubin, an early champion of the pharma breakup, figures Teva Pharmaceutical Industries could try it.
The President's Cancer Panel is urging federal and state health authorities to do a better job protecting children from preventable cancers by improving access to the HPV vaccine, which could mean a big bump in sales.
What if every drug in a class posed a risk to the heart--all except one? That's the question we could soon be asking about nonsteroidal anti-inflammatories, or NSAIDs, among the most commonly used drugs in the world.